Ischemic preconditioning protects the brain against injury via inhibiting CaMKII-nNOS signaling pathway

Brain Res. 2016 Mar 1:1634:140-149. doi: 10.1016/j.brainres.2016.01.008. Epub 2016 Jan 12.

Abstract

Although studies have shown that cerebral ischemic preconditioning (IPC) can ameliorate ischemia/reperfusion (I/R) induced brain damage, but its precise mechanisms remain unknown. Therefore, the aim of this study was to investigate the neuroprotective mechanisms of IPC against ischemic brain damage induced by cerebral I/R and to explore whether the Calcium/calmodulin-dependent protein kinase II (CaMKII)-mediated up-regulation of nNOS ser847-phosphorylation signaling pathway contributed to the protection provided by IPC. Transient global brain ischemia was induced by 4-vessel occlusion in adult male Sprague-Dawley rats. The rats were pretreated with 3 min of IPC alone or KN62 (selective antagonist of CaMKII) treatment before IPC, after reperfusion for 3 days, 6 min ischemia was induced. Cresyl violet staining was used to examine the survival of hippocampal CA1 pyramidal neurons. Immunoblotting was performed to measure the phosphorylation of CaMKII, nNOS, c-Jun and the expression of FasL. Immunoprecipitation was used to examine the binding between PSD95 and nNOS. The results showed that IPC could significantly protect neurons against cerebral I/R injury, furthermore, the combination of PSD95 and nNOS was increased, coinstantaneously the phosphorylation of CaMKII and nNOS (ser847) were up-regulated, however the activation of c-Jun and FasL were reduced. Conversely, KN62 treatment before IPC reversed all these effects of IPC. Taken together, the results suggest that IPC could diminish ischemic brain injury through CaMKII-mediated up-regulation of nNOS ser847-phosphorylation signaling pathway.

Keywords: CaMKII; FasL; Ischemic preconditioning; Neuroprotection; PSD95; c-Jun; nNOS.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine / analogs & derivatives
  • 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine / pharmacology
  • Animals
  • Apoptosis / drug effects
  • Brain Ischemia / metabolism*
  • CA1 Region, Hippocampal / drug effects
  • CA1 Region, Hippocampal / metabolism*
  • Calcium-Calmodulin-Dependent Protein Kinase Type 2 / antagonists & inhibitors
  • Calcium-Calmodulin-Dependent Protein Kinase Type 2 / metabolism*
  • Disks Large Homolog 4 Protein
  • Fas Ligand Protein / metabolism
  • Intracellular Signaling Peptides and Proteins / metabolism
  • Ischemic Preconditioning*
  • JNK Mitogen-Activated Protein Kinases / metabolism
  • Male
  • Membrane Proteins / metabolism
  • Neurons / drug effects
  • Neurons / metabolism
  • Nitric Oxide Synthase Type I / metabolism*
  • Phosphorylation
  • Rats
  • Rats, Sprague-Dawley
  • Reperfusion Injury / metabolism
  • Signal Transduction / drug effects

Substances

  • Disks Large Homolog 4 Protein
  • Dlg4 protein, rat
  • Fas Ligand Protein
  • Faslg protein, rat
  • Intracellular Signaling Peptides and Proteins
  • Membrane Proteins
  • KN 62
  • 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine
  • Nitric Oxide Synthase Type I
  • Calcium-Calmodulin-Dependent Protein Kinase Type 2
  • JNK Mitogen-Activated Protein Kinases